Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Designer drugs in psychiatric practice - a review of the literature and the recent situation in Hungary.

Szily E, Bitter I.

Neuropsychopharmacol Hung. 2013 Dec;15(4):223-31. Review.

2.

[Clinical characteristics of 5 hospitalized 3,4-methylenedioxypyrovalerone (MDPV) users].

Farkas K, Sirály E, Szily E, Csukly G, Réthelyi J.

Psychiatr Hung. 2013;28(4):431-9. Hungarian.

PMID:
24443577
3.

3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online.

Coppola M, Mondola R.

Toxicol Lett. 2012 Jan 5;208(1):12-5. doi: 10.1016/j.toxlet.2011.10.002. Epub 2011 Oct 8. Review.

PMID:
22008731
5.

Methylenedioxypyrovalerone ("bath salts"), related death: case report and review of the literature.

Kesha K, Boggs CL, Ripple MG, Allan CH, Levine B, Jufer-Phipps R, Doyon S, Chi P, Fowler DR.

J Forensic Sci. 2013 Nov;58(6):1654-9. doi: 10.1111/1556-4029.12202. Epub 2013 Jul 3. Review.

PMID:
23822613
6.

Current "legal highs".

Johnson LA, Johnson RL, Portier RB.

J Emerg Med. 2013 Jun;44(6):1108-15. doi: 10.1016/j.jemermed.2012.09.147. Epub 2013 Mar 23. Review.

PMID:
23528960
7.

Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order.

Drug Enforcement Administration, Department of Justice.

Fed Regist. 2011 Oct 21;76(204):65371-5.

8.

Letter to the Editor--Methylenedioxypyrovalerone as a cause of excited delirium.

Penders TM, Gestring RE.

J Forensic Sci. 2014 May;59(3):869. doi: 10.1111/1556-4029.12397. No abstract available.

PMID:
24749855
9.

Designer drugs 2015: assessment and management.

Weaver MF, Hopper JA, Gunderson EW.

Addict Sci Clin Pract. 2015 Mar 25;10:8. doi: 10.1186/s13722-015-0024-7.

10.

Deaths involving methylenedioxypyrovalerone (MDPV) in Upper East Tennessee.

Wright TH, Cline-Parhamovich K, Lajoie D, Parsons L, Dunn M, Ferslew KE.

J Forensic Sci. 2013 Nov;58(6):1558-62. doi: 10.1111/1556-4029.12260. Epub 2013 Aug 6.

PMID:
23919452
11.

"Not for human consumption": a review of emerging designer drugs.

Musselman ME, Hampton JP.

Pharmacotherapy. 2014 Jul;34(7):745-57. doi: 10.1002/phar.1424. Epub 2014 Apr 8. Review.

PMID:
24710806
12.

Hallucinatory delirium following use of MDPV: "Bath Salts".

Penders TM, Gestring R.

Gen Hosp Psychiatry. 2011 Sep-Oct;33(5):525-6. doi: 10.1016/j.genhosppsych.2011.05.014. Epub 2011 Jul 16. No abstract available.

PMID:
21762997
13.

Mephedrone and 3,4-Methylenedioxypyrovalerone (MDPV): Synthetic Cathinones With Serious Health Implications.

White CM.

J Clin Pharmacol. 2016 Nov;56(11):1319-1325. doi: 10.1002/jcph.742. Review.

PMID:
27029951
14.

Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification.

Thornton SL, Gerona RR, Tomaszewski CA.

J Med Toxicol. 2012 Sep;8(3):310-3. doi: 10.1007/s13181-012-0232-4.

15.

Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones.

Khullar V, Jain A, Sattari M.

J Gen Intern Med. 2014 Aug;29(8):1200-4. doi: 10.1007/s11606-014-2802-4. Epub 2014 Feb 20. Review.

16.

Bath salts and synthetic cathinones: an emerging designer drug phenomenon.

German CL, Fleckenstein AE, Hanson GR.

Life Sci. 2014 Feb 27;97(1):2-8. doi: 10.1016/j.lfs.2013.07.023. Epub 2013 Aug 2. Review.

17.

New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature.

Cottencin O, Rolland B, Karila L.

Curr Pharm Des. 2014;20(25):4106-11. Review.

PMID:
24001292
18.

Crystallographic investigations of select cathinones: emerging illicit street drugs known as `bath salts'.

Wood MR, Lalancette RA, Bernal I.

Acta Crystallogr C Struct Chem. 2015 Jan;71(Pt 1):32-8. doi: 10.1107/S2053229614025637. Epub 2015 Jan 1.

PMID:
25567572
19.

Emerging trends in the abuse of designer drugs and their catastrophic health effects: update on chemistry, pharmacology, toxicology and addiction potential.

Rapaka RS, Purohit V, Schnur P, Rutter J.

Life Sci. 2014 Feb 27;97(1):1. doi: 10.1016/j.lfs.2014.01.074. No abstract available.

PMID:
24529194
20.

Use of synthetic cannabinoids in patients with psychotic disorders: case series.

Celofiga A, Koprivsek J, Klavz J.

J Dual Diagn. 2014;10(3):168-73. doi: 10.1080/15504263.2014.929364.

PMID:
25392292

Supplemental Content

Support Center